It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Novel human astroviruses (HAstV) were discovered 10 years ago and have been associated with fatal cases of central nervous system infections. Their role in gastroenteritis is controversial, as they have been identified in symptomatic and asymptomatic subjects. The aim of the study was to investigate novel HAstV in a gastroenteritis case-control study including a pediatric population in Spain over a one-year period. We included stool samples from patients with gastroenteritis and negative results for viruses screened by routine diagnostics, and stool samples of control subjects who sought for a routine medical consultation. All samples were screened by real-time RT-PCR assays for novel HAstV. An additional screening for rotavirus, norovirus GI, GII, sapovirus, classic HAstV and adenovirus was also performed for the control group. Overall, 23/363 stool samples from case patients (6.3%) and 8/199 stool samples from control patients (4%) were positive for ≥1 novel HAstV. MLB1 was predominant (64.5% of positives). Seasonality was observed for the case group (p = 0.015), but not the control group (p = 0.95). No difference was observed in the prevalence of novel HAstV between the case and control groups (OR 1.78, 95% CI 0.68–5.45; p = 0.30). Nevertheless, MLB genome copy numbers/ml of fecal suspension was significantly higher in the control group than in the case group (p = 0.008). In our study, we identified a lack of association between novel HAstV and gastroenteritis in the studied population, which could indicate a potential role of reservoir for children, especially given the higher viral load observed in the asymptomatic group for some of them.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University of Barcelona, Enteric Virus Laboratory, Department of Genetics, Microbiology and Statistics, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); University of Barcelona, Nutrition and Food Safety Research Institute (INSA·UB), Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Geneva University Hospitals, Department of Infectious Diseases, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812)
2 University of Barcelona, Enteric Virus Laboratory, Department of Genetics, Microbiology and Statistics, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); University of Barcelona, Nutrition and Food Safety Research Institute (INSA·UB), Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
3 University of Barcelona, Enteric Virus Laboratory, Department of Genetics, Microbiology and Statistics, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
4 Generalitat de Catalunya, Primary Health Care Center El Serral, Sant Vicenç dels Horts, Spain (GRID:grid.454735.4) (ISNI:0000000123317762)
5 Hospital Universitari Vall d’Hebron, Microbiology Department, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)